Supplementary Figure 1. c Human

Size: px

Start display at page:

Download "Supplementary Figure 1. c Human"

Dora Patrick
6 years ago
Views:

SignalP 4.1 algorithm. (c) Amino acid sequence alignment of human and mouse MYDGF.

1 Supplementary Figure 1 a b c Human Mouse d Gapdh Amino acid sequence and baseline expression of MYDGF N-terminal signal peptides (S-scores) and signal peptide cleavage sites (C-scores) of (a) human MYDGF (C19orf1) and (b) mouse (D17Wsu14e) as predicted by the SignalP 4.1 algorithm. (c) Amino acid sequence alignment of human and mouse MYDGF. Identical and highly conserved (+) amino acids are shown. Signal peptides are highlighted in green. (d) Representative immunoblots (of three) showing and Gapdh expression in mouse tissues (LV, left ventricle).

Supplementary Figure 2 a Control VEGFA b c Branching points (per field) Closed tubes (per field) 8 6 4 2 4 3 2 1

formation We stimulated human coronary artery endothelial cells for 16 h with VEGFA (5 ng ml 1 ) and different

(a) Representative fluorescent images (1 ng ml 1 ). Scale bar, 2 µm.

2 Supplementary Figure 2 a Control VEGFA b c Branching points (per field) Closed tubes (per field) Control VEGFA Control VEGFA *** *** ** (ng ml -1 ) * ** *** (ng ml -1 ) Endothelial cell network formation We stimulated human coronary artery endothelial cells for 16 h with VEGFA (5 ng ml 1 ) and different concentrations of. We stained the cells with BCECF-AM for quantitative analysis. (a) Representative fluorescent images (1 ng ml 1 ). Scale bar, 2 µm. (b) Branching points and (c) closed tubes from 4 independent experiments. (b,c) Data are presented as the means ± s.e.m. *P <.5, **P <.1, ***P <.1 vs. control (one-way ANOVA with Dunnett s multiple comparison post hoc test).

3 Supplementary Figure 3 (4 pages) a MI 1 d / Gapdh (%) MI 3 d / Gapdh (%) Ly-6C low EC Ly-6C low Ly-6C low Ly-6C low MI 7 d 25 Bone marrow Spleen Peripheral blood / Gapdh (%) Ly-6C low Ly-6C low Ly-6C low Sham 1 d

4 Supplementary Figure 3 (cont.) b Infarcted region Ly-6C low c Infarcted region Endothelial cells

5 Supplementary Figure 3 (cont.) d Bone marrow Ly-6C low e Spleen Ly-6C low

for 1, 3, or 7 d. Control mice underwent a sham operation.

6 Supplementary Figure 3 (cont.) f Peripheral blood Ly-6Clow expression in inflammatory cells and endothelial cells after MI We induced myocardial infarction (MI) in mice by coronary artery ligation for 1 h followed by reperfusion for 1, 3, or 7 d. Control mice underwent a sham operation. (a) expression (RT-qPCR, normalized to Gapdh) in monocytes, Ly-6C low monocytes or macrophages, neutrophils,,, and endothelial cells (EC) isolated by FACS from the infarcted region of the left ventricle, bone marrow, spleen, and peripheral blood. Data obtained 3 d after MI are also presented in Fig. 4f. Shown are the means ± s.e.m. from 5 mice (infarcted heart) and 4 mice (bone marrow, spleen, and peripheral blood) 1 d after MI; 4 mice (infarcted heart and spleen), 5 mice (bone marrow), and 3 mice (peripheral blood) 3 d after MI; 4 mice (all organs) 7 d after MI; 5 mice (bone marrow), 3 mice (spleen), and 4 mice (peripheral blood) 1 d after sham surgery. We defined the expression in heart monocytes 3 d after MI as 1%. (b f) Gating strategy. Representative panels 3 d after MI. (b,c) Infarcted region. (d) Bone marrow. (e) Spleen. (f) Peripheral blood.

Supplementary Figure 4 (4 pages) a WT K 1 2 B 3 4 5 6 X b Sham MI WT KO WT KO

7 Supplementary Figure 4 (4 pages) a WT K 1 2 B X b Sham MI WT KO WT KO Vector Neo Gapdh 5. kb 3.4 kb KO Neo c WT K 11.3 kb 1 2 B X 1.4 kb d +/+ +/+ F6 +/ +/+ +/+ B8 +/ +/+ +/+ E5 +/ WT (11.3 kb) KO (1.4 kb) KO Neo e 664 bp f M +/ +/ / +/+ +/+ / / +/ WT K 1 2 B X WT (664 bp) 153 bp KO (153 bp) KO Neo

8 Supplementary Figure 4 (cont.) g 3 h WT KO 5 WT KO Time (d) Time (d)

9 Supplementary Figure 4 (cont.) i 1, 1, 1 WT KO 1 j 1 Ly-6C low Ly-6C low

(D17Wsu14e) genomic locus (wild-type, WT), the targeting construct (vector), and the targeted allele (knockout, KO). B, BamHI; K, KpnI; X, XbaI; Neo, neomycin resistance cassette.

Immunoblots show and Gapdh expression in the infarcted region of the left ventricle 3 d after reperfusion or sham operation. (c) Primer pair used for whole locus spanning genomic PCR analysis.

10 Supplementary Figure 4 (cont.) k WT KO l 6 Coverage N (per field) Junctions (per field) WT KO Generation and characterization at baseline of -deficient mice (a) Restriction map and intron and exon structure of the (D17Wsu14e) genomic locus (wild-type, WT), the targeting construct (vector), and the targeted allele (knockout, KO). B, BamHI; K, KpnI; X, XbaI; Neo, neomycin resistance cassette. (b) We induced myocardial infarction (MI) in WT and KO mice by 1 h coronary artery ligation followed by reperfusion. Control mice underwent a sham operation. Immunoblots show and Gapdh expression in the infarcted region of the left ventricle 3 d after reperfusion or sham operation. (c) Primer pair used for whole locus spanning genomic PCR analysis. (d) Genomic PCR analysis of 9 ES cell clones after electroporation of the targeting construct. We used clone E5 to generate chimeric mice. (e) Primer pairs used for PCR genotyping of WT and KO alleles. (f) Representative gel illustrating PCR genotyping results from 8 offspring of a heterozygous mating. M, molecular size marker. (g,h) We monitored postnatal body mass gain in (g) 12 WT and 8 KO male mice and (h) 8 WT and 11 KO female mice. Data are presented as the means ± s.e.m. (i) Number of circulating neutrophils,,, and and Ly-6C low monocytes in WT (n = 5) and KO (n = 5) mice under baseline conditions as assessed by flow cytometry. Data are presented as the means ± s.e.m. (j) Gating strategy. Representative panels are from a WT mouse. (k,l) Postnatal retinal angiogenesis in WT and KO mice. (k) Representative fluorescent images representing retinas from 5 d old WT and KO mice stained with fluorescein-labeled isolectin B4. Scale bar, 1 mm. (l) Number of angiogenic sprouts at the angiogenic front, vascular plexus complexity, and endothelial coverage of the retina. Summary data (means ± s.e.m.) are from 7 WT and 6 KO mice.

11 Supplementary Figure 5 LV pressure (mmhg) WT, sham KO, sham WT, MI KO, MI LV volume (µl) Pressure-volume loops in wild-type and knockout mice We induced myocardial infarction (MI) in wild-type (WT) and knockout (KO) mice by coronary artery ligation for 1 h followed by reperfusion. Control mice underwent a sham operation. Representative left ventricular (LV) pressure-volume loops were recorded 28 d after MI.

12 Supplementary Figure 6 a (per mg) cells (per mg) 5, 4, 3, 2, 1, 1, , WT KO b Time (d) Time (d) Time (d) Inflammatory cell accumulation after MI in wild-type and knockout mice Ly-6C low We induced myocardial infarction (MI) in wild-type (WT) and knockout (KO) mice by coronary artery ligation for 1 h followed by reperfusion. (a) Accumulation of neutrophils, monocytes, Ly-6C low monocytes or macrophages,, and in the infarcted region of the left ventricle as assessed by flow cytometry 1 d (5 WT, 5 KO), 3 d (4 WT, 3 KO), and 7 d (4 WT, 3 KO) after reperfusion. Data are presented as the means ± s.e.m. *P <.5 WT vs. KO, P =.6 WT vs. KO (two independent sample t-test). (b) Gating strategy. Representative panels are from a WT mouse 3 d after MI.

13 Supplementary Figure 7 a b c ** * ** ** KO KO WT KO WT WT KO WT KO KO WT KO WT WT KO WT FAC (%) KO KO * ** WT KO WT WT KO WT Importance of bone marrow cell-derived after MI We transplanted ( ) bone marrow cells from wild-type (WT) and knockout (KO) mice into lethally irradiated WT or KO recipients. After bone marrow reconstitution, we induced myocardial infarction (MI) by coronary artery ligation for 1 h followed by reperfusion. (a) Isolectin B4 (IB4) + endothelial cell density in the infarct border zone 28 d after reperfusion. CM, cardiac myocyte. 1 mice per group. Data are presented as means ± s.e.m. *P <.5, **P <.1 (two independent sample t-test). (b) Scar size 28 d after reperfusion. 1 mice per group. Data are presented as means ± s.e.m. **P <.1 (two independent sample t-test). (c) Fractional area change (FAC) as determined by echocardiography 28 d after reperfusion in 8 KO KO, 13 WT KO, 15 WT WT, and 12 KO WT mice. Scatter plot shows values from individual mice. Horizontal bars are the means. *P <.5, **P <.1 (two independent sample t-test).

14 Supplementary Figure 8 a Plasma (fold increase) Time (min) i.v. bolus b Plasma (fold increase) LV bolus 15 min Time (d) s.c. infusion Control Rec. 1h ischemia c Baseline 15 min Control 15 min Rec. 2 d 6 d 9 d 2 d 6 d 9 d Rec. Gapdh Pharmacokinetics of recombinant (a) plasma levels in 4 non-infarcted FVB/N mice as determined by targeted LC-MS at serial time points after i.v. (tail vein) bolus injection of recombinant (rec.) (1 µg). Data are presented as means ± s.e.m. (fold increase vs. baseline which is indicated by the dashed red line). Elimination of from plasma after 15 min followed a first-order kinetic (R² =.86) with an estimated half-life of 15.3 min (95% confidence interval min). (b,c) We induced myocardial infarction in FVB/N mice by coronary artery ligation for 1 h followed by reperfusion. We injected rec. (1 µg) into the left ventricular (LV) cavity at the time of reperfusion followed by s.c. infusion for 7 d (1µg d 1 ). We treated infarcted control mice with PBS. (b) plasma levels as determined by targeted LC-MS at serial time points. 5 mice per group and time point. Data are presented as means ± s.e.m. (fold increase vs. baseline which is indicated by the dashed red line). (c) Delivery of rec. to the infarcted region of the left ventricle as determined by anti-his-tag immunoblotting. Representative immunoblot (of four) illustrating rec. and Gapdh expression.

Supplementary Figure 9 a c - SP LacZ Gapdh Liver LacZ - SP LacZ Left ventricle - SP

*** - SP IB4 + cells (per CM) LacZ 1.4 1.2 1.

Representative immunoblots (of three) showing and Gapdh expression in the liver and left

β-galactosidase (lacz), full-length, or lacking the N-terminal signal peptide ( SP).

ligation for 1 h followed by reperfusion.

after reperfusion; extracellular matrix and cardiac myocyte (CM) borders are highlighted

***P <.1 vs. lacz (one-way ANOVA with Dunnett s multiple comparison post hoc test).

Representative tissue sections stained with Masson s trichrome. Scale bar, 1 mm.

(d) Fractional area change (FAC) as determined by echocardiography 6 and 28 d after

15 Supplementary Figure 9 a c - SP LacZ Gapdh Liver LacZ - SP LacZ Left ventricle - SP Infarct scar (% of LV) b IB4 DAPI WGA LacZ - SP LacZ d FAC (%) LacZ - SP *** - SP IB4 + cells (per CM) LacZ *** *** - SP LacZ - SP MI 6 d MI 28 d Adenoviral gene transfer in vivo (a) Representative immunoblots (of three) showing and Gapdh expression in the liver and left ventricle of FVB/N mice 7 d after i.v. infection with adenoviruses encoding β-galactosidase (lacz), full-length, or lacking the N-terminal signal peptide ( SP). (b d) 7 d after adenovirus infection, we induced myocardial infarction by coronary artery ligation for 1 h followed by reperfusion. (b) Fluoresceinlabeled isolectin B4 (IB4) + capillaries in the infarct border zone 28 d after reperfusion; extracellular matrix and cardiac myocyte (CM) borders are highlighted by WGA staining. Scale bar, 5µm. Summary data (means ± s.e.m.) are from 7 mice per group. ***P <.1 vs. lacz (one-way ANOVA with Dunnett s multiple comparison post hoc test). (c) Scar size 28 d after reperfusion. Representative tissue sections stained with Masson s trichrome. Scale bar, 1 mm. Summary data (means ± s.e.m.) from 16 LacZ, 15, and 9 - SP mice. ***P <.1 vs. lacz (one-way ANOVA with Dunnett s multiple comparison post hoc test). (d) Fractional area change (FAC) as determined by echocardiography 6 and 28 d after reperfusion in 17 LacZ, 15, and 9 - SP mice. Scatter plot shows values from individual mice. Horizontal bars are the means. ***P <.1 vs. lacz (for each time point one-way ANOVA with Dunnett s multiple comparison post hoc test).

16 Supplementary Figure 1 a Control b FAC (%) *** ### Sham MI, control MI, Delayed protein therapy after MI We induced myocardial infarction (MI) in FVB/N mice by coronary artery ligation for 1 h followed by reperfusion. Additional mice underwent a sham operation. We delivered by s.c. infusion for 7 d (1µg d 1 ) starting 6 h after reperfusion. We treated infarcted control mice with diluent only (PBS). (a) Scar size 28 d after reperfusion. Summary data (means ± s.e.m.) from 12 control and 14 -treated mice. **P <.1 (two independent sample t-test). (b) Fractional area change (FAC) as determined by echocardiography 28 d after reperfusion in 14 control mice, 16 -treated mice, and 6 sham-operated mice. Scatter plot shows values from individual mice. Horizontal bars are the means. ***P <.1 vs. both MI groups, ### P <.1 (one-way ANOVA with Tukey s multiple comparison post hoc test).

17 Supplementary Figure 11 (2 pages) a M P b kda M r (Da) M r UV V e (ml) c Anti-MYDGF No antibody Control IgG Input Eluate Beads Input Eluate Beads Input Eluate Beads d BrdU incorporation (%) Control -IP e BrdU incorporation (%) ** *** *** *** *** Control IgG ( g ml -1 ) Anti-MYDGF ( g ml -1 )

18 Supplementary Figure 11 (cont.) Production and validation of recombinant (a) SDS-PAGE analysis of the final recombinant protein preparation. We applied marker proteins (M, Mark12 Novex, Life Technologies) and 5 µl of the final protein preparation (P) to a 4 12% polyacrylamide gel. We stained the proteins with Coomassie Blue after electrophoresis. (b) Analytical size exclusion chromatography of the final protein preparation. The relative protein concentration (UV) and the absolute molecular mass (M r ) from the region of the chromatographic peak, as computed via the basic lightscattering equation, are plotted against the elution volume (V e ). (c) We immunoprecipitated from the final protein preparation using Dynabeads coated with the MYDGF antibody. We analyzed aliquots from the final protein preparation (input), the protein eluted from the beads (eluate), and the beads after protein elution (beads) by immunoblotting. We repeated the experiment using beads coated with no antibody or with control IgG. (d) We stimulated human coronary artery endothelial cells (HCAECs) with recombinant (1 ng ml 1 ) and immunoprecipitated from the final protein preparation (IP, 1 ng ml 1 ). We assessed BrdU incorporation after 16 h. 4 independent experiments. ***P <.1 vs. control (one-way ANOVA with Dunnett s multiple comparison post hoc test). (e) We stimulated HCAECs with recombinant (1 ng ml 1 ) in the presence or absence of various concentrations of the MYDGF antibody or control IgG. We assessed BrdU incorporation after 16 h. Control: 6 independent experiments. IgG alone: 3 independent experiments. Other conditions: 4 independent experiments. **P <.1, ***P <.1 vs. without antibody (one-way ANOVA with Dunnett s multiple comparison post hoc test).

19 Supplementary Table 1. List of candidate proteins Official full name (official symbol) NCBI Reference Sequence D- score Biological activities (% of control) Cardiac myocytes MTS assay NNscore Caspase- 3 and 7 activity Endothelial cells BrdU Closed tubes Candidate proteins possibly secreted via the classical secretory pathway Ly6/neurotoxin 1 (LYNX1) NM_ Chromosome 19 open reading frame 1 (C19orf1) NM_ Chromosome 1 open reading frame 99 (C1orf99) NM_ Podocan-like 1 (PODNL1) NM_ Chitinase domain containing 1 (CHID1) AF ER membrane protein complex subunit 1 (EMC1) NM_ Chromosome 12 open reading frame 39 (C12orf39) NM_ Von Willebrand factor C and EGF domains (VWCE) NM_ Arylsulfatase A (ARSA) NP_478.3 Cysteine-rich with EGF-like domains 2 (CRELD2).957 n.d. 1 ± 6 16 ± ± 8 13 ± 3.88 n.d. 154 ± ± ± ± n.d. 12 ± ± ± ± n.d. 144 ± 1 63 ± 2 19 ± 2 11 ± n.d. 124 ± 8 76 ± ± ± n.d. 11 ± 4 82 ± ± 2 14 ± 7.86 n.d. 135 ± 2 8 ± ± 3 97 ± 5.81 n.d. 19 ± 8 89 ± 8 18 ± 2 12 ± n.d. 85 ± 4 11 ± 2 11 ± 9 11 ± n.d. 94 ± 6 15 ± 6 97 ± 1 48 ± 4 1

20 NM_24324 Prenylcysteine oxidase 1 like (PCYOX1L) NM_ Chromosome X open reading frame 36 (CXorf36) NM_ Chromosome 1 open reading frame 54 (C1orf54) NM_24579 Chromosome 11 open reading frame 94 (C11orf94) NM_ Family with sequence similarity 96, member A (FAM96A) NM_ Family with sequence similarity 131, member A (FAM131A) NM_ Family with sequence similarity 172, member A (FAM172A) NM_ Inositol 1,4,5-trisphosphate receptor interacting protein (ITPRIP) NM_ Uncharacterized protein DKFZp667F711 AL Isoamyl acetate-hydrolyzing esterase 1 homolog (S. cerevisiae) (IAH1) NM_ n.d. 18 ± 2 18 ± ± 4 99 ± 6.75 n.d. 11 ± 6 11 ± ± 2 98 ± n.d. 11 ± 1 95 ± 8 19 ± 6 98 ± n.d. 19 ± 6 99 ± 2 17 ± 3 58 ± n.d. 142 ± 1 7 ± 7 13 ± 7 14 ± n.d. 177 ± 4 82 ± ± 3 17 ± n.d. 13 ± ± ± 2 17 ± 6.61 n.d. 111 ± 5 14 ± 8 63 ± ± n.d. 114 ± ± ± 1 99 ± n.d. 94 ± 2 93 ± 5 12 ± 5 99 ± 7 2

21 Candidate proteins possibly secreted via non-classical secretory pathways Chromosome 2 open reading frame 196 (C2orf196) NM_ Uncharacterized protein PRO2214 AF Chromosome 9 open reading frame 16 (C9orf16) NM_ Chromosome 6 open reading frame 226 (C6orf226) NM_ Methyltransferase like 5 (METTL5) NM_ Chromosome 1 open reading frame 11 (C1orf11) NM_ BRICK1, SCAR/WAVE actinnucleating complex subunit (BRK1) NM_ R3H domain containing 4 (R3HDM4) NM_ Family with sequence similarity 13, member A1 (FAM13A1) NM_ KIAA513 NM_ FANCD2 opposite strand (FANCD2OS) NM_ ± 6 58 ± ± ± ± 2 15 ± ± ± ± 4 9 ± 4 16 ± 3 14 ± ± 4 13 ± ± 2 14 ± ± ± ± ± ± ± ± 8 12 ± ± ± ± ± ± ± ± 3 99 ± ± ± 7 14 ± ± ± 8 98 ± ± 9 97 ± ± 4 96 ± ± ± 5 3

22 LSM12 homolog (S. cerevisiae) (LSM12) NM_ Proline-rich coiled-coil 1 (PRRC1) NM_ Coiled-coil domain containing 43 (CCDC43) NM_ Family with sequence similarity 136, member A (FAM136A) NM_ Migration and invasion enhancer 1 (MIEN1) NM_ Chromosome 1 open reading frame 21 (C1orf21) NM_386.3 Parkinson disease 7 domain containing 1 (PDDC1) NM_ Methyltransferase like 23 (METTL23) NM_ Chromosome 17 open reading frame 72 (C17orf72) NM_ Chromosome 18 open reading frame 54 (C18orf54) NM_ Family with sequence similarity 78, member A (FAM78A) NM_ ± ± 9 14 ± 9 19 ± ± 6 94 ± 7 12 ± 6 1 ± ± ± 6 12 ± ± ± 6 99 ± ± 2 12 ± ± 2 99 ± ± ± ± ± 7 96 ± 4 95 ± ± 7 96 ± ± 3 17 ± ± 6 17 ± ± 5 12 ± ± 1 12 ± 9 11 ± 6 16 ± ± 4 14 ± ± 8 11 ± ± ± ± 5 18 ± 4 4

23 Positive controls Growth differentiation factor 15 (GDF15) NM_ Vascular endothelial growth factor A (VEGFA) NM_ n.d. 148 ± 6 52 ± 3 n.d. n.d..859 n.d. n.d. n.d. 121 ± 3 13 ± 1 List of candidate proteins possibly secreted via the classical secretory pathway (D-score >.45) or via non-classical secretory pathways (D-score <.45; NN-score >.5). Candidate proteins and positive controls (GDF15, VEGFA) were expressed individually in HEK-293 cells to obtain conditioned supernatants for functional screens in serum-starved neonatal rat ventricular myocytes (MTS assay, caspase-3 and -7 activity assay) and human coronary artery endothelial cells (BrdU incorporation, closed tube formation). C19orf1 is highlighted in blue. Data are presented as the means ± s.e.m. from at least 3 independent experiments. 5

24 Supplementary Table 2. PCR genotyping of 431 offspring from heterozygous matings WT +/ KO Total Males 59 (25.8) 19 (47.6) 61 (26.6) 229 (1) Females 47 (23.3) 12 (5.5) 53 (26.2) 22 (1) wild-type (WT), heterozygous (+/ ), and knockout (KO) mice. Data are presented as numbers (percentage).

25 Supplementary Table 3. Baseline phenotype of wild-type and knockout mice WT KO Gravimetry Body mass (g) 25.2 ± ±.8 Lung mass per body mass (mg g 1 ) 7.6 ± ±.6 Liver mass per body mass (mg g 1 ) 56.5 ± ± 6.3 Kidney mass per body mass (mg g 1 ) 6.4 ± ±.8 Spleen mass per body mass (mg g 1 ) 5.1 ± ±.3 LV mass per body mass (mg g 1 ) 4.2 ± ±.1 Echocardiography LVEDA (mm 2 ) 16.6 ± ±.7 LVESA (mm 2 ) 8.1 ± ±.3 Fractional area change (%) 49.8 ± ±.7 Tail-cuff plethysmography Systolic blood pressure (mmhg) 112 ± ± 3.9 Diastolic blood pressure (mmhg) 68 ± ± 5.3 Heart rate (min 1 ) 7 ± 1 71 ± 7 Baseline phenotype of 8 1 weeks old wild-type (WT) and knockout (KO) mice. Gravimetry and echocardiography, 16 mice per genotype; tail-cuff plethysmography, 8 mice per genotype. LV denotes left ventricular; LVEDA, LV end-diastolic area; LVESA, LV endsystolic area.

26 Supplementary Table 4. Left ventricular pressure-volume measurements in wild-type and knockout mice Heart rate (min 1 ) LV end-systolic pressure (mmhg) LV end-diastolic pressure (mmhg) LV end-systolic volume (µl) LV end-diastolic volume (µl) LV ejection fraction (%) dp/dt max (mmhg s 1 ) dp/dt min (mmhg s 1 ) τ (ms) WT sham KO sham WT MI KO MI 451 ± ± ± ± ± ± 8 17 ± 3* 98 ± 2* 14 ± 2 12 ± 1 14 ± 2 15 ± 2 14 ± 2 11 ± 2 3 ± 3* 45 ± 4***, ## 37 ± 2 34 ± 1 46 ± 4 56 ± 4** 71 ± 4 72 ± 4 41 ± 4*** 26 ± 3***, # 1,47 ± 864 1,685 ± 644 8,728 ± 999 6,64 ± 29** -9,57 ± 446-9,82 ± 332-7,41 ± 69* -5,373 ± 176***, # 8.4 ± ± ± ±.5** Myocardial infarction (MI) was induced in wild-type (WT, n = 8) and knockout (KO, n = 7) mice by 1 h coronary artery ligation followed by reperfusion. Control mice underwent a sham operation (5 mice per genotype). We recorded left ventricular (LV) pressure-volume loops after 28 d. Data are presented as the means ± s.e.m. *P <.5, **P <.1, ***P <.1 vs. same genotype sham, # P <.5, ## P <.1 KO MI vs. WT MI (two-way ANOVA with Tukey s multiple comparison post hoc test).

Kidney. Heart. Lung. Sirt1. Gapdh. Mouse IgG DAPI. Rabbit IgG DAPI

Kidney. Heart. Lung. Sirt1. Gapdh. Mouse IgG DAPI. Rabbit IgG DAPI a e Na V 1.5 Ad-LacZ Ad- 110KD b Scn5a/ (relative to Ad-LacZ) f 150 100 50 0 p = 0.65 Ad-LacZ Ad- c Heart Lung Kidney Spleen 110KD d fl/fl c -/- DAPI 20 µm Na v 1.5 250KD fl/fl Rabbit IgG DAPI fl/fl Mouse